197 related articles for article (PubMed ID: 27299298)
1. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
Cañadas-Garre M; Becerra-Massare P; Moreno Casares A; Calleja-Hernández MÁ; Llamas-Elvira JM
Head Neck; 2016 Dec; 38(12):1772-1779. PubMed ID: 27299298
[TBL] [Abstract][Full Text] [Related]
2. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
3. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.
Fakhruddin N; Jabbour M; Novy M; Tamim H; Bahmad H; Farhat F; Zaatari G; Aridi T; Kriegshauser G; Oberkanins C; Mahfouz R
Sci Rep; 2017 Jul; 7(1):4666. PubMed ID: 28680105
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
5. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
Melo M; Gaspar da Rocha A; Batista R; Vinagre J; Martins MJ; Costa G; Ribeiro C; Carrilho F; Leite V; Lobo C; Cameselle-Teijeiro JM; Cavadas B; Pereira L; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2017 Jun; 102(6):1898-1907. PubMed ID: 28323937
[TBL] [Abstract][Full Text] [Related]
6. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
7. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
8. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
9. A mutation panel comprising BRAF
Eng ZH; Ahmad Jefry MM; Ng KL; Abdul Aziz A; Mat Junit S
Malays J Pathol; 2023 Dec; 45(3):375-390. PubMed ID: 38155379
[TBL] [Abstract][Full Text] [Related]
10. How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
Xu B; Serrette R; Tuttle RM; Alzumaili B; Ganly I; Katabi N; Tallini G; Ghossein R
Thyroid; 2019 Dec; 29(12):1792-1803. PubMed ID: 31452453
[No Abstract] [Full Text] [Related]
11. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
12. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status.
Cradic KW; Milosevic D; Rosenberg AM; Erickson LA; McIver B; Grebe SK
J Clin Endocrinol Metab; 2009 Dec; 94(12):5001-9. PubMed ID: 19850689
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma.
Danilovic DL; Lima EU; Domingues RB; Brandão LG; Hoff AO; Marui S
Eur J Endocrinol; 2014 Apr; 170(4):619-25. PubMed ID: 24468978
[TBL] [Abstract][Full Text] [Related]
14. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.
Cordioli MI; Moraes L; Bastos AU; Besson P; Alves MT; Delcelo R; Monte O; Longui C; Cury AN; Cerutti JM
Thyroid; 2017 Feb; 27(2):182-188. PubMed ID: 27849443
[TBL] [Abstract][Full Text] [Related]
15. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
[TBL] [Abstract][Full Text] [Related]
16. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.
Giannini R; Ugolini C; Lupi C; Proietti A; Elisei R; Salvatore G; Berti P; Materazzi G; Miccoli P; Santoro M; Basolo F
J Clin Endocrinol Metab; 2007 Sep; 92(9):3511-6. PubMed ID: 17535994
[TBL] [Abstract][Full Text] [Related]
17. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
[TBL] [Abstract][Full Text] [Related]
18. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis.
Walts AE; Pao A; Sacks W; Bose S
Hum Pathol; 2014 May; 45(5):935-41. PubMed ID: 24746198
[TBL] [Abstract][Full Text] [Related]
19. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients.
Cañadas-Garre M; Becerra-Massare P; López de la Torre-Casares M; Villar-del Moral J; Céspedes-Mas S; Vílchez-Joya R; Muros-de Fuentes T; García-Calvente C; Piédrola-Maroto G; López-Nevot MA; Montes-Ramírez R; Llamas-Elvira JM
Ann Surg; 2012 May; 255(5):986-92. PubMed ID: 22504197
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
